Foresite Capital Management V, LLC — 13F Holdings & Portfolio
CIK 1792206 · latest 13F-HR filed 2026-05-15
Foresite Capital Management V, LLC manages $271.0M in 13F-reported U.S. long-equity assets across 9 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ALMS (47.94%), CGON (25.08%), IRON (8.83%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 3 new positions, exited 1, added to 3, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$271.0M
Long-equity book
9
Distinct positions
2026-03-31
Filed 2026-05-15
+3 / −1 / ↑3 / ↓2
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALUMIS INC.$73.5M +130.3%
- CG Oncology, Inc.$26.3M +63.0%
- Hims & Hers Health, Inc.$6.5M +72.8%
New Positions
- Eikon Therapeutics, Inc.$14.0M
- Pharvaris N.V.$5.5M
- Nurix Therapeutics, Inc.$4.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ALUMIS INC. | ALMS | 022307102 | $129.9M | 47.94% | 5,896,995 | SH |
| 2 | CG Oncology, Inc. | CGON | 156944100 | $68.0M | 25.08% | 1,004,050 | SH |
| 3 | Disc Medicine, Inc. | IRON | 254604101 | $23.9M | 8.83% | 374,069 | SH |
| 4 | Hims & Hers Health, Inc. | HIMS | 433000106 | $15.3M | 5.65% | 738,151 | SH |
| 5 | Eikon Therapeutics, Inc. | EIKN | 282564103 | $14.0M | 5.15% | 1,318,983 | SH |
| 6 | Lyell Immunopharma, Inc. | LYEL | 55083R203 | $9.6M | 3.53% | 477,078 | SH |
| 7 | Pharvaris N.V. | PHVS | N69605108 | $5.5M | 2.02% | 194,125 | SH |
| 8 | Nurix Therapeutics, Inc. | NRIX | 67080M103 | $4.1M | 1.52% | 265,000 | SH |
| 9 | Maze Therapeutics, Inc. | MAZE | 578784100 | $773.3K | 0.29% | 25,905 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $271.0M | 9 | 0001104659-26-062464 |
| 2025-12-31 | 2026-02-17 | $164.4M | 7 | 0001104659-26-015410 |
| 2025-09-30 | 2025-11-14 | $108.7M | 6 | 0001104659-25-112503 |